Immediate Impact
2 by Nobel laureates 3 from Science/Nature 55 standout
Citing Papers
Analysis of Breast Cancer Mortality in the US—1975 to 2019
2024 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
Works of Judith Klimovsky being referenced
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Everolimus plus octreotide LAR (E+O) versus placebo plus octreotide LAR (P+O) in patients with advanced neuroendocrine tumors (NET): Updated results of a randomized, double-blind, placebo-controlled, multicenter phase III trial (RADIANT-2).
2011
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Judith Klimovsky | 1524 | 813 | 290 | 590 | 27 | 1.8k | |
| Allan Topham | 1162 | 303 | 675 | 176 | 25 | 2.5k | |
| Emanuele Palescandolo | 469 | 503 | 815 | 223 | 19 | 1.6k | |
| Stefano Barbi | 916 | 694 | 534 | 360 | 33 | 1.6k | |
| Shem Patyna | 1845 | 1517 | 532 | 1120 | 32 | 2.5k | |
| Arlene Berman | 1278 | 108 | 614 | 432 | 47 | 2.4k | |
| A. Hennipman | 1566 | 469 | 567 | 87 | 39 | 2.5k | |
| Idris Tolgay Ocal | 407 | 180 | 340 | 264 | 53 | 1.5k | |
| Jeremie Lincy | 1859 | 1661 | 660 | 1154 | 19 | 2.8k | |
| Yutaka Kawakami | 901 | 542 | 766 | 53 | 36 | 2.4k | |
| Svetlana Bolshakov | 608 | 134 | 799 | 255 | 31 | 1.9k |
All Works
Loading papers...